Skip to main content Skip to main navigation menu Skip to site footer
Scientific Electronic Archives
Health Science
DOI: 10.36560/15420221527
Submitted: 2022-01-06
Published: 2022-04-01

Application of techniques involving miRNA in autoimmune immunological processes: an analysis of national productions carried out in the last decade

Universidade Estadual do Sudoeste da Bahia
biologia molecular; biotecnologia; imunologia

Abstract

The immune system is made up of several components that harmoniously protect us against different pathogens. However, due to little-known events, this system ends up losing the ability to discriminate what is proper to the organism from what is not, triggering autoimmune diseases. Among the different ways that researchers have been using to study and, consequently, develop therapies for the treatment of these diseases, the manipulation of miRNA's stands out. Taking into account that this technology is recent and that it is necessary to understand what is already systematized so that it is possible to observe any gaps in scientific knowledge and, based on them, set new goals, this work aims to analyze how national productions have pointed out the use of miRNA-based techniques related to autoimmune diseases. For this purpose, bibliographic searches were performed on the academic Google, Scielo, PubMed and MedLine platforms, using the following descriptors: Application; Autoimmune; miRNA; Immunological processes. 86 productions were obtained, being 55 analyzed. After analysis, four categories were inferred: studies related to the development of T and B cells; Analysis of miRNA associated with autoimmune diseases in general; Analysis of miRNA associated with specific autoimmune diseases; and miRNA-associated therapies. In addition to being possible to investigate the following gaps: incomplete knowledge of the biological processes carried out by miRNA's, the lack of techniques that make it possible to manipulate the RNA given its instability, the lack of knowledge about the behavior of the genome and, in the case of the national scope, the lack of investment both to train labor and to provide adequate infrastructure. Thus, it is concluded that there is an urgent need for research with objectives not only in the application of techniques associated with miRNA, but also in the understanding of this machinery, so that we can understand which structures are involved in the process carried out by these molecules and how they can - they will be manipulated for therapeutic purposes.

References

  1. ABBAS, Abul K.; PILLAI,Shiv; LICHTMAN, Andrew H.. Imunologia: Celular e Molecular. 9 ed. Rio De Janeiro: Editora Elsevier Ltda, 2019.
  2. ALATAS, E. T.; KARA, M.; DOGAN, G.; BELLI, A. A. Expressões de microRNA no sangue em pacientes com psoríase leve a moderada e relação entre microRNAs e atividade da psoríase. Anais Brasileiros de Dermatologia, v. 95, n. 6, p. 702-707, 2020.
  3. AMARILYO, G.; CAVA, A. la. miRNA in systemic lupus erythematosus. Clinical immunology, v. 144, n. 1, p. 26-31, 2012.
  4. BACH, J. F. The etiology of autoimmune diseases: the case of myasthenia gravis. Annals of the New York Academy of Sciences, v. 1274, n. 1, p. 33-39, 2012.
  5. BARDIN, L. Análise de conteúdo. São Paulo: Edições, v. 70, p. 229, 2011.
  6. BAXTE, D.; MCINNES, I. B.; KUROWSKA‐STOLARSKA, M. Novel regulatory mechanisms in inflammatory arthritis: a role for microRNA. Immunology and cell biology, v. 90, n. 3, p. 288-292, 2012.
  7. CERIBELLI, A.; SATOH, M.; CHAN, E. K. MicroRNAs and autoimmunity. Current opinion in immunology, v. 24, n. 6, p. 686-691, 2012.
  8. COSTA, A. L. P.; SILVA-JÚNIOR, A. C. S.; PINHEIRO, A. L. Fatores associados à etiologia e patogênese das doenças autoimunes. Arquivos Catarinenses de Medicina, v. 48, n. 2, p. 92-106, 2019.
  9. DENG, X.; SU, Y.; WU, H.; WU, R.; ZHANG, P.; DAI, Y.; CHAN, T.-M.; ZHAO, M.; LU, Q. The Role of Micro RNA s in Autoimmune Diseases with Skin Involvement. Scandinavian journal of immunology, v. 81, n. 3, p. 153-165, 2015.
  10. FILHO, J. R.; KIMURA, E. T. MicroRNAs: nova classe de reguladores gênicos envolvidos na função endócrina e câncer. Arquivos Brasileiros de Endocrinologia & Metabologia, v. 50, p. 1102-1107, 2006.
  11. FORTE, W. C. N. Imunologia do básico ao aplicado. 2 ed. Porto Alegre: Artmed, 2007.
  12. FRANÇA, N. R. D.; JÚNIOR, D. M.; LIMA, A. B.; PUCCI, F. V. C.; ANDRADE, L. E. C.; SILVA, N. P. Interferência por RNA: Uma nova alternativa para terapia nas doenças reumáticas. Revista Brasileira de Reumatologia, v. 50, p. 695-702, 2010.
  13. GARO, L. P.; MURUGAIYAN, G. Contribution of MicroRNAs to autoimmune diseases. Cellular and Molecular Life Sciences, v. 73, n. 10, p. 2041-2051, 2016.
  14. GOTTER, J.; KYEWSKI, B. Regulating self-tolerance by deregulating gene expression. Current opinion in immunology, v. 16, n. 6, p. 741-745, 2004.
  15. HA, M.; KIM, V. Narry. Regulation of microRNA biogenesis. Nature reviews Molecular cell biology, v. 15, n. 8, p. 509-524, 2014.
  16. JADIDESLAM, G.; ANSARIN, K.; SAKHINIA, E.; BABALOO, Z.; ABHARI, A.; ALIPOUR, S.; KHABBAZI, A. Expression levels of miR-21, miR-146b and miR-326 as potential biomarkers in Behcet's disease. Biomarkers in medicine, v. 13, n. 16, p. 1339-1348, 2019.
  17. KING, Peter H.; CHEN, Ching-Yi. Role of KSRP in control of type I interferon and cytokine expression. Journal of Interferon & Cytokine Research, v. 34, n. 4, p. 267-274, 2014.
  18. KSIAZEK-WINIAREK, D. J.; KACPERSKA, M. J.; GLABINSKI, A. MicroRNAs as novel regulators of neuroinflammation. Mediators of inflammation, v. 2013, 2013.
  19. KUMAR, P.; SUBRAMANIYAM, G. Molecular underpinnings of Th17 immune-regulation and their implications in autoimmune diabetes. Cytokine, v. 71, n. 2, p. 366-376, 2015.
  20. LI, B.; WANG, X.; CHOI, I. Y.; WANG, Y. C.; LIU, S.; PHAM, A. T.; YANG, L. miR-146a modulates autoreactive Th17 cell differentiation and regulates organ-specific autoimmunity. The Journal of clinical investigation, v. 127, n. 10, p. 3702-3716, 2017.
  21. LÖFGREN, S. E.; FROSTEGÅRD, J.; TRUEDSSON, L.; PONS-ESTEL, B. A.; D'ALFONSO, S.; WITTE, T.; ALARCÓN-RIQUELME, M. E. Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes & Immunity, v. 13, n. 3, p. 268-274, 2012.
  22. LU, J.; YAN, M.; WANG, Y.; ZHANG, J.; YANG, H.; TIAN, F. F.; LI, J. Altered expression of miR-146a in myasthenia gravis. Neuroscience letters, v. 555, p. 85-90, 2013.
  23. MAREGA, L. F.; TEOCCHI, M. A.; VILELA, M. M. dos. S. Differential regulation of miR‐146a/FAS and miR‐21/FASLG axes in autoimmune lymphoproliferative syndrome due to FAS mutation (ALPS‐FAS). Clinical & Experimental Immunology, v. 185, n. 2, p. 148-153, 2016.
  24. MENCK, C. F. M. A nova grande promessa da inovação em fármacos: RNA interferência saindo do laboratório para a clínica. estudos avançados, v. 24, p. 99-108, 2010.
  25. MIRA, R.; SORIANO, L. G.; CUNHA, C. B.; NASCIMENTO, R. C. Lúpus Eritematoso Sistêmico: Novos Paradigmas e Manejo no Atendimento Emergencial–Revisão de Literatura. Revista Científica Hospital Santa Izabel, v. 4, n. 1, p. 57-62, 2020.
  26. MORAIS, A. K. S. de; COSTA, A. P. R. da. Papel do microRNA na regulação da expressão gênica e sua associação com a oncogênese: biomarcadores para leucemia mielóide aguda. Caderno de Graduação-Ciências Biológicas e da Saúde-UNIT-PERNAMBUCO, v. 3, n. 3, p. 53-53, 2018.
  27. MURUGAIYAN, G.; GARO, L. P.; WEINER, H. L. MicroRNA-21, T helper lineage and autoimmunity. Oncotarget, v. 6, n. 12, p. 9644, 2015.
  28. O'CONNELL, R. M.; RAO, D. S.; BALTIMORE, D. microRNA regulation of inflammatory responses. Annual review of immunology, v. 30, p. 295-312, 2012.
  29. OLINA, A. V.; KULBACHINSKIY, A. V.; ARAVIN, A. A.; ESYUNINA, D. Argonaute proteins and mechanisms of RNA interference in eukaryotes and prokaryotes. Biochemistry, v. 83, n. 5, p. 483-497, 2018.
  30. ORHAN, G.; ERUYAR, E.; MUNGAN, S. Ö.; AK, F.; KARAHALIL, B. The association of IL-18 gene promoter polymorphisms and the levels of serum IL-18 on the risk of multiple sclerosis. Clinical neurology and neurosurgery, v. 146, p. 96-101, 2016.
  31. PACHECO, C.; CECCATTO, V. M.; MAIA, C. M.; ROSA, S. D. S. R. F.; LEITE, C. R. M. Pesquisa translacional na era pós-genômica: avanços na área da transcriptômica. Saúde em Debate, v. 43, p. 169-180, 2020.
  32. PRABAHAR, A.; NATARAJAN, J.. MicroRNA mediated network motifs in autoimmune diseases and its crosstalk between genes, functions and pathways. Journal of immunological methods, v. 440, p. 19-26, 2017.
  33. QU, Z.; LI, W.; FU, B. MicroRNAs in autoimmune diseases. BioMed Research International, v. 2014, n., p. 1-8, 2014.
  34. REIS, A. P.; FERNANDES, K.; JEHEE, F. S. MicroRNAs: papel no diagnóstico e tratamento da asma. Arquivos de Asma, Alergia e Imunologia, v. 3, n. 3, p. 86-92, 2015.
  35. SALAMA, A.; FICHOU, N.; ALLARD, M.; DUBREIL, L.; BEAUREPAIRE, L.; VIEL, A.; JÉGOU, D.; BÖSCH, S.; BACH, J. M. MicroRNA-29b modulates innate and antigen-specific immune responses in mouse models of autoimmunity. PloS one, v. 9, n. 9, p. e106153, 2014.
  36. SELMI, C. Hot topics in autoimmune diseases: perspectives from the 2013 Asian Congress of Autoimmunity. Autoimmunity reviews, v. 13, n. 8, p. 781-787, 2014.
  37. SIMPSON, L. J.; ANSEL, K. M. MicroRNA regulation of lymphocyte tolerance and autoimmunity. The Journal of clinical investigation, v. 125, n. 6, p. 2242-2249, 2015.
  38. SINGH, R. P.; MASSACHI, I.; MANICKAVEL, S.; SINGH, S.; RAO, N. P.; HASAN, S.; REHIMI, H. The role of miRNA in inflammation and autoimmunity. Autoimmunity reviews, v. 12, n. 12, p. 1160-1165, 2013.
  39. SUN, Y.; ZHANG, W.; LI, B.; ZOU, Z.; SELMI, C.; GERSHWIN, M. E. The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review. Clinical reviews in allergy & immunology, v. 48, n. 2-3, p. 301-315, 2015.
  40. TANG, X.; TANG, R.; XU, Y.; WANQ, Q.; HOU, Y.; SHEN, S.; WANG, T. MicroRNA networks in regulatory T cells. Journal of physiology and biochemistry, v. 70, n. 3, p. 869-875, 2014.
  41. TORELLA, D.; IACONETTI, C.; TARALLO, R.; MARINO, F.; GIURATO, G.; VENEZIANO, C.; INDOLFI, C. miRNA regulation of the hyperproliferative phenotype of vascular smooth muscle cells in diabetes. Diabetes, v. 67, n. 12, p. 2554-2568, 2018.
  42. VARGAS, M. M.; STOLF-MOREIRA, R. Aplicação de microRNAs na prática clínica. Revista Brasileira Clinica Medica, [S. l.], v. 11, n. 1, p. 62-6, 2013.
  43. YAMANISHI, T.; CHIKAMATSU, K.; TAKAHASHI, G.; ENDO, S.; MASUYAMA, K. Immune regulation by CD4+ CD25+ regulatory T cells in patients with Japanese cedar pollinosis. International archives of allergy and immunology, v. 156, n. 2, p. 187-195, 2011.
  44. YANG, Y.; PENG, L.; MA, W.; YI, F.; ZHANG, Z.; CHEN, H.; DU, Q. Autoantigen-targeting microRNAs in Sjögren’s syndrome. Clinical rheumatology, v. 35, n. 4, p. 911-917, 2016.
  45. ZENG, L.; WU, J. L.; LIU, L. M.; JIANG, J. Q.; WU, H. J.; ZHAO, M.; LU, Q. J. Serum miRNA-371b-5p and miRNA-5100 act as biomarkers for systemic lupus erythematosus. Clinical Immunology, v. 196, p. 103-109, 2018..

How to Cite

Santos, L. A. . (2022). Application of techniques involving miRNA in autoimmune immunological processes: an analysis of national productions carried out in the last decade. Scientific Electronic Archives, 15(4). https://doi.org/10.36560/15420221527